ARTVArtiva Biotherapeutics, Inc.
Health Care
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents revised up 0.6% for Q1 2024
This is the 2nd largest revision in ARTV's history.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Q1 2024
As reported
$40.2MRestated
$40.5M0.6%
Verify against SEC filingsShow
As reported$40.2M
Accepted 2025-05-080000950170-25-066421
Restated$40.5M
Accepted 2026-05-080001193125-26-213242
CashAndEquivalents · reported 3 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get an alert the next time ARTV — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.